Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Tuberculosis | Research

The clinical profile and outcomes of drug resistant tuberculosis in Central Province of Zambia

Author: Evaristo Chanda

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

The emergence of Drug Resistant Tuberculosis (DR-TB) is one of the main public health and economic problems facing the world today. DR-TB affects mostly those in economically productive years and prevents them from being part of the workforce needed for economic growth. The aim of this study was to determine the Clinical Profile and Outcomes of DR-TB in Central Province of Zambia.

Methods

This was a retrospective cross sectional study that involved a review of records of patients with confirmed DR-TB who were managed at Kabwe Central Hospital’s Multi-Drug Resistant TB (MDR-TB) Ward from the year 2017 to 2021. 183 patients were managed during this period and all were recruited in the study. Data was collected from DR-TB registers and patient files and then entered in SPSS version 22 where all statistical analyses were performed.

Results

The study revealed that the prevalence of DR-TB among registered TB patients in Central Province was 1.4%. Majority of those affected were adults between the ages of 26 and 45 years (63.9%). The study also found that more than half of the patients were from Kabwe District (60.7%). Other districts with significant number of cases included Kapiri Mposhi 19 (10.4%), Chibombo 12 (6.6%), Chisamba 10 (5.5%), Mumbwa 7 (3.8%) and Mkushi 7 (3.8%). Furthermore, the analysis established that most of the patients had RR-TB (89.6%). 9.3% had MDR-TB, 0.5% had IR-TB and 0.5% had XDR-TB. RR-TB was present in 93.8% of new cases and 88.9% of relapse cases. MDR-TB was present in 6.2% of new cases and 10% of relapse cases. With regard to outcomes of DR-TB, the investigation revealed that 16.9% of the patients had been declared cured, 45.9% had completed treatment, 6% were lost to follow up and 21.3% had died. Risk factors for mortality on multivariate analysis included age 36–45 years (adjusted odds ratio [aOR] 0.253, 95% CI [0.70–0.908] p = 0.035) and male gender (aOR 0.261, 95% CI [0.107–0.638] p = 0.003).

Conclusion

The research has shown beyond doubt that the burden of DR-TB in Central Province is high. The study recommends putting measures in place that will help improve surveillance, early detection, early initiation of treatment and proper follow up of patients.
Literature
2.
go back to reference Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Elsevier Ltd/Inc/BV; 2013. p. 2013. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Elsevier Ltd/Inc/BV; 2013. p. 2013.
3.
go back to reference Jain A, Mondal R. Extensively drug-resistant tuberculosis: current challenges and threats. FEMS Immunol Med Microbiol. 2008;2008(53):145–50.CrossRef Jain A, Mondal R. Extensively drug-resistant tuberculosis: current challenges and threats. FEMS Immunol Med Microbiol. 2008;2008(53):145–50.CrossRef
4.
go back to reference Isara AR, Akpodiete A. Concerns about the knowledge and attitude of multidrug-resistant tuberculosis among health care workers and patients in Delta state, Nigeria. Niger J Clin Pract. 2015;18(5). Isara AR, Akpodiete A. Concerns about the knowledge and attitude of multidrug-resistant tuberculosis among health care workers and patients in Delta state, Nigeria. Niger J Clin Pract. 2015;18(5).
5.
6.
go back to reference World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization; 2014. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization; 2014.
8.
go back to reference Cox H, Dickson-Hall L, Jassat W, et al. Drug-resistant tuberculosis in South Africa: history, progress and opportunities for achieving universal access to diagnosis and effective treatment. SAHR – 20 Year Anniversary Edition, 2017. Cox H, Dickson-Hall L, Jassat W, et al. Drug-resistant tuberculosis in South Africa: history, progress and opportunities for achieving universal access to diagnosis and effective treatment. SAHR – 20 Year Anniversary Edition, 2017.
9.
go back to reference World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
10.
go back to reference World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug – resistant tuberculosis treatment. World health Organization; 2020. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug – resistant tuberculosis treatment. World health Organization; 2020.
11.
go back to reference World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
13.
go back to reference Nunes AE, De Capitani EM, Coelho E, et al. Patterns of anti-tuberculosis drug resistance among HIV-infected patients in Maputo, Mozambique, 2002–2003. Int J Tuberc Lung Dis. 2005;9(5):494–500.PubMed Nunes AE, De Capitani EM, Coelho E, et al. Patterns of anti-tuberculosis drug resistance among HIV-infected patients in Maputo, Mozambique, 2002–2003. Int J Tuberc Lung Dis. 2005;9(5):494–500.PubMed
14.
go back to reference Mahla SR. Prevalence of drug – resistant tuberculosis in South Africa. Lancet Infect Dis. 2018;18(8):386.CrossRef Mahla SR. Prevalence of drug – resistant tuberculosis in South Africa. Lancet Infect Dis. 2018;18(8):386.CrossRef
15.
go back to reference Kapata N, Mbulo G, Cobelens F, et al. The second Zambian National Tuberculosis Drug Resistance survey – a comparison of conventional and molecular methods. Trop Med Int Health. 2015;20(11):1492–500.CrossRefPubMed Kapata N, Mbulo G, Cobelens F, et al. The second Zambian National Tuberculosis Drug Resistance survey – a comparison of conventional and molecular methods. Trop Med Int Health. 2015;20(11):1492–500.CrossRefPubMed
16.
go back to reference World Health Organization. Multidrug-resistant tuberculosis (MDR-TB). World Health Organization; 2019. World Health Organization. Multidrug-resistant tuberculosis (MDR-TB). World Health Organization; 2019.
17.
go back to reference Ngoma T. Distribution of drug-resistant tuberculosis in Zambia, 2008–2011. Dissertation Submitted in Partial Fulfillment of the Requirement for the Degree of Master of Public Health. The University of Zambia, Lusaka; 2015. Ngoma T. Distribution of drug-resistant tuberculosis in Zambia, 2008–2011. Dissertation Submitted in Partial Fulfillment of the Requirement for the Degree of Master of Public Health. The University of Zambia, Lusaka; 2015.
21.
go back to reference Park M, Satta G, Kon MO. An update on multidrug-resistant tuberculosis. Clin Med. 2019;19(2):135–9.CrossRef Park M, Satta G, Kon MO. An update on multidrug-resistant tuberculosis. Clin Med. 2019;19(2):135–9.CrossRef
22.
go back to reference Ministry of Health of Zambia. National Strategic Plan for Tuberculosis and Leprosy Prevention, Care, and Control (2022–2026). Ministry of Health; 2022. Ministry of Health of Zambia. National Strategic Plan for Tuberculosis and Leprosy Prevention, Care, and Control (2022–2026). Ministry of Health; 2022.
23.
24.
go back to reference Akwaowo CD, Ekpin V, Umoh V, Jiman O, Bassey A, Antia E, Usoroh E. Prevalence and outcomes of multi drug resistant tuberculosis in Akwa Ibom state Nigeria: a retrospective study. World J Appl Sci Technol. 2021;13(1):10–8. Akwaowo CD, Ekpin V, Umoh V, Jiman O, Bassey A, Antia E, Usoroh E. Prevalence and outcomes of multi drug resistant tuberculosis in Akwa Ibom state Nigeria: a retrospective study. World J Appl Sci Technol. 2021;13(1):10–8.
25.
go back to reference The Economist Intelligence Unit. It’s time to end drug-resistant tuberculosis: the case for action. The Economist Intelligence Unit Limited; 2019. The Economist Intelligence Unit. It’s time to end drug-resistant tuberculosis: the case for action. The Economist Intelligence Unit Limited; 2019.
28.
go back to reference World Health Organization. The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. World Health Organization; 2015. World Health Organization. The end TB strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. World Health Organization; 2015.
29.
go back to reference Baya B, Achenbach JC, Kone B, et al. Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. Int J Infect Dis. 2019;81:149–55.CrossRefPubMedPubMedCentral Baya B, Achenbach JC, Kone B, et al. Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. Int J Infect Dis. 2019;81:149–55.CrossRefPubMedPubMedCentral
30.
go back to reference Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798–807.CrossRefPubMed Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798–807.CrossRefPubMed
40.
go back to reference Mwiinga V. Prevalence of multi-drug resistant tuberculosis among adult patients at Ndola central hospital, Ndola, Zambia. South Am J Public Health. 2015;3(4). Mwiinga V. Prevalence of multi-drug resistant tuberculosis among adult patients at Ndola central hospital, Ndola, Zambia. South Am J Public Health. 2015;3(4).
43.
go back to reference Chewe W, Chansa A, Lungu P, Liusha N. Extrapulmonary drug resistant tuberculosis in Zambia: case reports on the first two recorded cases. Med J Zambia. 2020;47(1):154–9.CrossRef Chewe W, Chansa A, Lungu P, Liusha N. Extrapulmonary drug resistant tuberculosis in Zambia: case reports on the first two recorded cases. Med J Zambia. 2020;47(1):154–9.CrossRef
44.
go back to reference van Kampen S, van Cleeff M, van Gorkom J, Rehr M. TB CARE I Core project: Intensified implementation of GeneXpert MTB/RIF in 3 Countries March 2011 – March 2013. Final report. KNCV Tuberculosis Foundation; 2013. van Kampen S, van Cleeff M, van Gorkom J, Rehr M. TB CARE I Core project: Intensified implementation of GeneXpert MTB/RIF in 3 Countries March 2011 – March 2013. Final report. KNCV Tuberculosis Foundation; 2013.
45.
go back to reference Institute of Medicine. The global crisis of DrugResistant tuberculosis and leadership of China and the BRICS: challenges and opportunities: summary of a joint workshop. Washington, DC: The National Academies Press; 2014. Institute of Medicine. The global crisis of DrugResistant tuberculosis and leadership of China and the BRICS: challenges and opportunities: summary of a joint workshop. Washington, DC: The National Academies Press; 2014.
46.
go back to reference Atashi S, Izadi B, Jalilian S, Madani HS, Farahani A, Mohajeri P. Evaluation of GeneXpert MTB/RIF for determination of rifampicin resistance among new tuberculosis cases in west and Northwest Iran. New Microbes New Infect. 2017;19 Number C. Atashi S, Izadi B, Jalilian S, Madani HS, Farahani A, Mohajeri P. Evaluation of GeneXpert MTB/RIF for determination of rifampicin resistance among new tuberculosis cases in west and Northwest Iran. New Microbes New Infect. 2017;19 Number C.
48.
go back to reference Ministry of Health of Zambia. The National Tuberculosis and leprosy control program: guidelines for the programmatic Management of Drug-Resistant Tuberculosis in Zambia. 3rd ed. Ministry of Health of Zambia; 2017. Ministry of Health of Zambia. The National Tuberculosis and leprosy control program: guidelines for the programmatic Management of Drug-Resistant Tuberculosis in Zambia. 3rd ed. Ministry of Health of Zambia; 2017.
52.
go back to reference Muluneh AM, Zeru AB, Derseh TB, Kebede MA. Survival Status and Predictors of Mortality among Multidrug-Resistant Tuberculosis Patients in Saint Peter’s Specialized Hospital, Addis Ababa, Ethiopia. Hindawi Can J Infect Dis Med Microbiol. 2021;6696199:9. https://doi.org/10.1155/2021/6696199. Muluneh AM, Zeru AB, Derseh TB, Kebede MA. Survival Status and Predictors of Mortality among Multidrug-Resistant Tuberculosis Patients in Saint Peter’s Specialized Hospital, Addis Ababa, Ethiopia. Hindawi Can J Infect Dis Med Microbiol. 2021;6696199:9. https://​doi.​org/​10.​1155/​2021/​6696199.
56.
go back to reference Adepoju VA, Adelekan A, Adejumo AO. Timing and reasons for lost to follow-up among patients on 6-month standardized anti-TB treatment in Nigeria. J Pre-Clin Clin Res. 2022;16(2):34–7.CrossRef Adepoju VA, Adelekan A, Adejumo AO. Timing and reasons for lost to follow-up among patients on 6-month standardized anti-TB treatment in Nigeria. J Pre-Clin Clin Res. 2022;16(2):34–7.CrossRef
67.
go back to reference World Health Organization. Tuberculosis: women and TB. World Health Organization; 2009. World Health Organization. Tuberculosis: women and TB. World Health Organization; 2009.
Metadata
Title
The clinical profile and outcomes of drug resistant tuberculosis in Central Province of Zambia
Author
Evaristo Chanda
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09238-8

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.